Drug Profile
Research programme: galanin receptor 3 antagonists - Dart NeuroScience
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Helicon Therapeutics
- Developer Dart NeuroScience
- Class
- Mechanism of Action Galanin type 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Memory disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Memory disorders in USA
- 01 Jan 2012 Helicon Therapeutics has been acquired and merged into Dart NeuroScience
- 11 Apr 2011 Preclinical trials in Memory disorders in USA (unspecified route)